Please report any queries concerning the funding data grouped in the sections named "Externally Awarded" or "Internally Disbursed" (shown on the profile page) to
your Research Finance Administrator. Your can find your Research Finance Administrator at https://www.ucl.ac.uk/finance/research/rs-contacts.php by entering your department
Please report any queries concerning the student data shown on the profile page to:
Email: portico-services@ucl.ac.uk
Help Desk: http://www.ucl.ac.uk/ras/portico/helpdesk
Email: portico-services@ucl.ac.uk
Help Desk: http://www.ucl.ac.uk/ras/portico/helpdesk
› More search options
Dr Lucy Chisman-Russell
Dementia Research Centre
8-11 Queen Square
London
WC1N 3AR
Tel: 020 344 83653
Appointment
- Research Fellow
- Neurodegenerative Diseases
- UCL Queen Square Institute of Neurology
- Faculty of Brain Sciences
Biography
2011-2015: BSc (Hons) Psychology from the University of Plymouth with a placement year at the Social, Genetic and Psychiatry Centre, Kings College London (2013-2014)
2015-2019: Research Assistant at the Dementia Research Centre, University College London
2016-2020: PhD in neuroscience from University College London
2020-Present: Research Fellow at the Dementia Research Centre, University College London
Research Summary
I am a postdoctoralresearcher funded by the Bluefield Project. I have a BSc in Psychology fromthe University of Plymouth and joined the Dementia Research Centre as aresearch assistant after graduating in 2015. She worked as the co-ordinator ofthe Longitudinal Investigation of Frontotemporal Dementia (LIFTD) study andthen started a part-time PhD in 2016 alongside this work. My PhD investigatedthe role of social cognition in FTD which included individuals from LIFTD, aswell as from an international familial FTD study known as the GeneticFrontotemporal Dementia Initiative (GENFI). As part of my PhD, I alsodeveloped a novel set of instructionless eye tracking tasks to study socialcognition in FTD. She is now working as the co-ordinator of the FTD PreventionInitiative (FPI), helping to link together the genetic FTD cohort studies around the world, and liaising with pharmaceutical companies as new therapeutictrials start for individuals with FTD.
